enprofylline has been researched along with Obstructive Lung Diseases in 8 studies
enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Long-term ambulatory Holter-monitoring was used to evaluate the arrhythmogenic effects of beta 2-agonist therapy, alone and in combination with a xanthine derivative, theophylline or enprofylline." | 6.66 | Cardiac arrhythmias in patients with mild-to-moderate obstructive lung disease. Comparison of beta-agonist therapy alone and in combination with a xanthine derivative, enprofylline or theophylline. ( Conradson, TB; Eklundh, G; Olofsson, B; Pahlm, O; Persson, G, 1985) |
| "Theophylline was administered in identical doses, except that the final dosage increase was not made if plasma theophylline was 12 mg/ml or higher." | 2.67 | A comparison of enprofylline and theophylline in the maintenance therapy of chronic reversible obstructive airway disease. ( Abboud, RT; Boucher, S; Chapman, KR; Day, A; Hodder, RV; Hyland, RH; Kreisman, H; Peters, S; Rivington, R; York, EL, 1990) |
| "Long-term ambulatory Holter-monitoring was used to evaluate the arrhythmogenic effects of beta 2-agonist therapy, alone and in combination with a xanthine derivative, theophylline or enprofylline." | 2.66 | Cardiac arrhythmias in patients with mild-to-moderate obstructive lung disease. Comparison of beta-agonist therapy alone and in combination with a xanthine derivative, enprofylline or theophylline. ( Conradson, TB; Eklundh, G; Olofsson, B; Pahlm, O; Persson, G, 1985) |
| " Neither at the low nor at the high dosage (2 +/- 4 mg/kg), giving plasma concentrations of 8." | 2.65 | Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease. ( Andersson, KE; Lunell, E; Persson, CG; Svedmyr, N, 1982) |
| "Enprofylline was given intravenously, 2 mg/kg, and measurements were done after ten and 30 min." | 1.27 | Cardiopulmonary effects of enprofylline. A xanthine with weak adenosine receptor antagonism in patients with severe chronic lung disease. ( Folling, M; Gulsvik, A; Vik-Mo, H, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lunell, E | 1 |
| Svedmyr, N | 1 |
| Andersson, KE | 1 |
| Persson, CG | 3 |
| Fozard, JR | 1 |
| Hannon, JP | 1 |
| Arnold, JD | 1 |
| Courtenay-Evans, RJ | 1 |
| Whitfield, R | 1 |
| O'Reilly, JF | 1 |
| Petrie, GR | 1 |
| Higgins, AJ | 1 |
| Swift, CG | 1 |
| Chapman, KR | 1 |
| Boucher, S | 1 |
| Hyland, RH | 1 |
| Day, A | 1 |
| Kreisman, H | 1 |
| Rivington, R | 1 |
| Hodder, RV | 1 |
| York, EL | 1 |
| Abboud, RT | 1 |
| Peters, S | 1 |
| Conradson, TB | 1 |
| Eklundh, G | 1 |
| Olofsson, B | 1 |
| Pahlm, O | 1 |
| Persson, G | 1 |
| Vik-Mo, H | 1 |
| Gulsvik, A | 1 |
| Folling, M | 1 |
2 reviews available for enprofylline and Obstructive Lung Diseases
| Article | Year |
|---|---|
Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Humans; Ligands; Lung Diseases, Obstr | 1999 |
Development of safer xanthine drugs for treatment of obstructive airways disease.
Topics: Adenosine; Animals; Asthma; Brain; Cardiovascular System; Humans; Lung; Lung Diseases, Obstructive; | 1986 |
4 trials available for enprofylline and Obstructive Lung Diseases
| Article | Year |
|---|---|
Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease.
Topics: Adult; Aged; Clinical Trials as Topic; Female; Forced Expiratory Volume; Hemodynamics; Humans; Lung | 1982 |
Comparative assessment of enprofylline and theophylline for chronic obstructive airways disease in the elderly.
Topics: Aged; Bronchodilator Agents; Double-Blind Method; Female; Headache; Humans; Lung Diseases, Obstructi | 1990 |
A comparison of enprofylline and theophylline in the maintenance therapy of chronic reversible obstructive airway disease.
Topics: Adolescent; Adult; Aged; Bronchodilator Agents; Delayed-Action Preparations; Dose-Response Relations | 1990 |
Cardiac arrhythmias in patients with mild-to-moderate obstructive lung disease. Comparison of beta-agonist therapy alone and in combination with a xanthine derivative, enprofylline or theophylline.
Topics: Adrenergic beta-Agonists; Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind | 1985 |
2 other studies available for enprofylline and Obstructive Lung Diseases
| Article | Year |
|---|---|
Cardiopulmonary effects of enprofylline. A xanthine with weak adenosine receptor antagonism in patients with severe chronic lung disease.
Topics: Adult; Aged; Aged, 80 and over; Cardiac Catheterization; Cardiac Pacing, Artificial; Cardiovascular | 1988 |
[Enprofylline--a new therapeutic possibility in asthma and other obstructive lung diseases].
Topics: Asthma; Bronchodilator Agents; Humans; Lung Diseases, Obstructive; Xanthines | 1985 |